Compare VALN & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VALN | XOMA |
|---|---|---|
| Founded | 2012 | 1981 |
| Country | France | United States |
| Employees | N/A | 14 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 536.9M | 471.6M |
| IPO Year | 2021 | N/A |
| Metric | VALN | XOMA |
|---|---|---|
| Price | $5.47 | $38.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $15.50 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 126.9K | 126.1K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $24.59 |
| Revenue Next Year | $93.87 | N/A |
| P/E Ratio | ★ N/A | $29.64 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.15 | $22.29 |
| 52 Week High | $12.25 | $40.74 |
| Indicator | VALN | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 29.34 | 66.95 |
| Support Level | N/A | $32.73 |
| Resistance Level | $6.42 | $39.89 |
| Average True Range (ATR) | 0.27 | 1.59 |
| MACD | 0.08 | -0.20 |
| Stochastic Oscillator | 28.74 | 64.16 |
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.